Literature DB >> 19141678

Niacin stimulates adiponectin secretion through the GPR109A receptor.

Eric P Plaisance1, Martina Lukasova, Stefan Offermanns, Youyan Zhang, Guoqing Cao, Robert L Judd.   

Abstract

Niacin (nicotinic acid) has recently been shown to increase serum adiponectin concentrations in men with the metabolic syndrome. However, little is known about the mechanism(s) by which niacin regulates the intracellular trafficking and secretion of adiponectin. Since niacin appears to exert its effects on lipolysis through receptor (GPR109A)-dependent and -independent pathways, the purpose of this investigation was to examine the role of the recently identified GPR109A receptor in adiponectin secretion. Initial in vivo studies in rats demonstrated that niacin (30 mg/kg po) acutely increases serum adiponectin concentrations, whereas it decreases NEFAs. Further in vitro studies demonstrated an increase in adiponectin secretion and a decrease in lipolysis in primary adipocytes following treatment with niacin or beta-hydroxybutyrate (an endogenous ligand of the GPR109A receptor), but these effects were blocked when adipocytes were pretreated with pertussis toxin. Niacin had no effect on adiponectin secretion or lipolysis in 3T3-L1 adipocytes, which have limited cell surface expression of the GPR109A receptor. To further substantiate these in vitro findings, wild-type and GPR109A receptor knockout mice were administered a single dose of niacin or placebo, and serum was obtained for the determination of adiponectin and NEFA concentrations. Serum adiponectin concentrations increased and serum NEFAs decreased in the wild-type mice within 10 min following niacin administration. However, niacin administration had no effect on adiponectin and NEFA concentrations in the GPR109A receptor knockout mice. These results demonstrate that the GPR109A receptor plays an important role in the dual regulation of adiponectin secretion and lipolysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141678     DOI: 10.1152/ajpendo.91004.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  41 in total

1.  Dietary nicotinic acid supplementation ameliorates chronic alcohol-induced fatty liver in rats.

Authors:  Qiong Li; Guoxiang Xie; Wenliang Zhang; Wei Zhong; Xiuhua Sun; Xiaobing Tan; Xinguo Sun; Wei Jia; Zhanxiang Zhou
Journal:  Alcohol Clin Exp Res       Date:  2014-05-21       Impact factor: 3.455

2.  Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.

Authors:  Ashok Balasubramanyam; Ivonne Coraza; E O'Brian Smith; Lynne W Scott; Payal Patel; Dinakar Iyer; Addison A Taylor; Thomas P Giordano; Rajagopal V Sekhar; Pamela Clark; Edith Cuevas-Sanchez; Swarna Kamble; Christie M Ballantyne; Henry J Pownall
Journal:  J Clin Endocrinol Metab       Date:  2011-05-11       Impact factor: 5.958

3.  Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.

Authors:  Sony Tuteja; Lu Wang; Richard L Dunbar; Jinbo Chen; Stephanie DerOhannessian; Santica M Marcovina; Marshall Elam; Ellis Lader; Daniel J Rader
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

Review 4.  Niacin in cardiovascular disease: recent preclinical and clinical developments.

Authors:  Janet E Digby; Neil Ruparelia; Robin P Choudhury
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-12-29       Impact factor: 8.311

5.  Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.

Authors:  Martina Lukasova; Camille Malaval; Andreas Gille; Jukka Kero; Stefan Offermanns
Journal:  J Clin Invest       Date:  2011-02-07       Impact factor: 14.808

6.  Prior ingestion of exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance test in healthy young individuals.

Authors:  Étienne Myette-Côté; Helena Neudorf; Hossein Rafiei; Kieran Clarke; Jonathan Peter Little
Journal:  J Physiol       Date:  2018-03-02       Impact factor: 5.182

7.  A microfluidic interface for the culture and sampling of adiponectin from primary adipocytes.

Authors:  Leah A Godwin; Jessica C Brooks; Lauren D Hoepfner; Desiree Wanders; Robert L Judd; Christopher J Easley
Journal:  Analyst       Date:  2015-02-21       Impact factor: 4.616

8.  A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1.

Authors:  Alip Borthakur; Shubha Priyamvada; Anoop Kumar; Arivarasu A Natarajan; Ravinder K Gill; Waddah A Alrefai; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-13       Impact factor: 4.052

9.  A meta-analysis of genome-wide association studies for adiponectin levels in East Asians identifies a novel locus near WDR11-FGFR2.

Authors:  Ying Wu; He Gao; Huaixing Li; Yasuharu Tabara; Masahiro Nakatochi; Yen-Feng Chiu; Eun Jung Park; Wanqing Wen; Linda S Adair; Judith B Borja; Qiuyin Cai; Yi-Cheng Chang; Peng Chen; Damien C Croteau-Chonka; Marie P Fogarty; Wei Gan; Chih-Tsueng He; Chao A Hsiung; Chii-Min Hwu; Sahoko Ichihara; Michiya Igase; Jaeseong Jo; Norihiro Kato; Ryuichi Kawamoto; Christophor W Kuzawa; Jeannette J M Lee; Jianjun Liu; Ling Lu; Thomas W McDade; Haruhiko Osawa; Wayne H-H Sheu; Yvonne Teo; Swarooparani Vadlamudi; Rob M Van Dam; Yiqin Wang; Yong-Bing Xiang; Ken Yamamoto; Xingwang Ye; Terri L Young; Wei Zheng; Jingwen Zhu; Xiao-Ou Shu; Chol Shin; Sun Ha Jee; Lee-Ming Chuang; Tetsuro Miki; Mitsuhiro Yokota; Xu Lin; Karen L Mohlke; E Shyong Tai
Journal:  Hum Mol Genet       Date:  2013-10-08       Impact factor: 6.150

10.  Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin.

Authors:  Janet E Digby; Eileen McNeill; Oliver J Dyar; Vincent Lam; David R Greaves; Robin P Choudhury
Journal:  Atherosclerosis       Date:  2009-08-31       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.